Company Profile
Bolt Biotherapeutics Stock Price, News & Analysis
- Ticker:
- BOLT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.87 USD (-2.03%)
Close
Last updated: August 6, 2026
9.82M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, BOLT closed down 2.03% at $3.87. No new same-company headline was identified in the current news window.
Company overview
Immune-Stimulating Antibody Conjugates
Bolt Biotherapeutics develops Boltbody immune-stimulating antibody conjugates that combine tumor targeting with activation of innate and adaptive immunity.
BDC-4182
BDC-4182 targets claudin 18.2 and is being evaluated in gastric, gastroesophageal junction, pancreatic, and other solid tumors.
Mechanistic Positioning
The program is designed to combine antibody-drug conjugate-like precision with durable immune activation associated with T-cell-engaging therapies.
Future catalysts
Initial Phase 1/2 BDC-4182 clinical data in gastric and gastroesophageal cancers are expected in the third quarter of 2026.
Recent news
- 01
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Source: Bolt Biotherapeutics
- 02
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
Source: Bolt Biotherapeutics
- 03
Bolt Biotherapeutics to Participate in Upcoming March Conferences
Source: Bolt Biotherapeutics
- 04
Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Source: Bolt Biotherapeutics
- 05
Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027
Source: Bolt Biotherapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Bolt Biotherapeutics (BOLT)?
Bolt Biotherapeutics (BOLT) most recently closed at 3.87 USD, a -2.03% move versus the previous session.
What is the market cap of Bolt Biotherapeutics (BOLT)?
Bolt Biotherapeutics currently has a market capitalization of 9.82M USD on BioPharmSignal.
What does Bolt Biotherapeutics do?
Immune-Stimulating Antibody Conjugates Bolt Biotherapeutics develops Boltbody immune-stimulating antibody conjugates that combine tumor targeting with activation of innate and adaptive immunity. BDC-4182 BDC-4182 targets claudin 18.2 and is being evaluated in gastric, gastroesophageal junction, pancreatic, and other solid tumors. Mechanistic Positioning The...
On which exchange is BOLT stock listed?
Bolt Biotherapeutics (BOLT) is associated with NASDAQ, United States, Biopharma.
What is BDC-4182?
Initial Phase 1/2 BDC-4182 clinical data in gastric and gastroesophageal cancers are expected in the third quarter of 2026.
Which conditions is Bolt Biotherapeutics targeting with BDC-4182?
Bolt Biotherapeutics is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Bolt Biotherapeutics describe recent progress with BDC-4182?
Initial Phase 1/2 BDC-4182 clinical data in gastric and gastroesophageal cancers are expected in the third quarter of 2026.
What is Immune-Stimulating?
Immune-Stimulating Antibody Conjugates Bolt Biotherapeutics develops Boltbody immune-stimulating antibody conjugates that combine tumor targeting with activation of innate and adaptive immunity.